This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levine, D. A. Articles by Boyd, J. Search for Related Content PubMed PubMed Citation Articles by Levine, D. A. Articles by Boyd, J.

Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers

Authors' Affiliations: ¹ Gynecology and Breast Research Laboratory, Department of Surgery, ² Clinical Genetics Service, Department of Medicine, and ³ Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York

Requests for reprints: Jeff Boyd, Department of Surgery, Box 201, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; Phone: 212-639-8608; Fax: 212-717-3538; E-mail: boydj{at}mskcc.org.

Purpose: Activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, resulting in increased cell proliferation, survival, and motility, is believed to play an oncogenic role in many cancer types. The PIK3CA gene encodes the p110 catalytic subunit of PI3K, and is amplified in some ovarian cancers, whereas the AKT2 gene is amplified in some ovarian, breast, and pancreatic cancers. Recently, in a mutational screen of eight PI3K genes and eight PI3K-like genes, PIK3CA was found to be the only gene affected by somatic mutations, which were observed frequently in gastrointestinal and brain cancers. Here, we test whether PIK3CA is subject to mutation in ovarian and breast cancers.

Experimental Design: Exons 9 and 20, encoding the highly conserved helical and kinase domains of PIK3CA, were subjected to sequence analysis in 198 advanced stage epithelial ovarian carcinomas and 72 invasive breast carcinomas (48 of ductal histology and 24 of lobular histology).

Results: Somatic missense mutations were observed in 24 of 198 (12%) ovarian carcinomas, and in 13 of 72 (18%) breast carcinomas.

Conclusions: These data indicate that mutations of PIK3CA play an oncogenic role in substantial fractions of ovarian and breast carcinomas, and in consideration of mutation of other components of the PI3K-AKT pathway in both tumor types, confirm the major oncogenic role of this pathway in ovarian and breast carcinomas.

Key Words: PIK3CA • ovarian cancer • breast cancer • oncogene • kinase

This article has been cited by other articles:

				Y.-L. Lai, B.-L. Mau, W.-H. Cheng, H.-M. Chen, H.-H. Chiu, and C.-Y. Tzen PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients Ann. Surg. Oncol., April 1, 2008; 15(4): 1064 - 1069. [Abstract] [Full Text] [PDF]

				R. E. Board, N. J. Thelwell, P. F. Ravetto, S. Little, M. Ranson, C. Dive, A. Hughes, and D. Whitcombe Multiplexed Assays for Detection of Mutations in PIK3CA Clin. Chem., April 1, 2008; 54(4): 757 - 760. [Abstract] [Full Text] [PDF]

				A. Astanehe, D. Arenillas, W. W. Wasserman, P. C. K. Leung, S. E. Dunn, B. R. Davies, G. B. Mills, and N. Auersperg Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer J. Cell Sci., March 1, 2008; 121(5): 664 - 674. [Abstract] [Full Text] [PDF]

				L. Zhao and P. K. Vogt Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms PNAS, February 19, 2008; 105(7): 2652 - 2657. [Abstract] [Full Text] [PDF]

				C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations Science, December 14, 2007; 318(5857): 1744 - 1748. [Abstract] [Full Text] [PDF]

				M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro, A. Ferro, P. Dalla Palma, E. Galligioni, and A. Marchetti Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas Clin. Cancer Res., October 15, 2007; 13(20): 6064 - 6069. [Abstract] [Full Text] [PDF]

				L. Zhang, J. Huang, N. Yang, J. Greshock, S. Liang, K. Hasegawa, A. Giannakakis, N. Poulos, A. O'Brien-Jenkins, D. Katsaros, et al. Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5314 - 5321. [Abstract] [Full Text] [PDF]

				G. Perez-Tenorio, L. Alkhori, B. Olsson, M. A. Waltersson, B. Nordenskjold, L. E. Rutqvist, L. Skoog, and O. Stal PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer Clin. Cancer Res., June 15, 2007; 13(12): 3577 - 3584. [Abstract] [Full Text] [PDF]

				M. Nanjundan, Y. Nakayama, K. W. Cheng, J. Lahad, J. Liu, K. Lu, W.-L. Kuo, K. Smith-McCune, D. Fishman, J. W. Gray, et al. Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer Cancer Res., April 1, 2007; 67(7): 3074 - 3084. [Abstract] [Full Text] [PDF]

				M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt Rare cancer-specific mutations in PIK3CA show gain of function PNAS, March 27, 2007; 104(13): 5569 - 5574. [Abstract] [Full Text] [PDF]

				N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, and S. Noguchi Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women Clin. Cancer Res., January 15, 2007; 13(2): 408 - 414. [Abstract] [Full Text] [PDF]

				E. Buck, A. Eyzaguirre, E. Brown, F. Petti, S. McCormack, J. D. Haley, K. K. Iwata, N. W. Gibson, and G. Griffin Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther., November 1, 2006; 5(11): 2676 - 2684. [Abstract] [Full Text] [PDF]

				M. P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G. J. Solomon, S. J. Baker, and L. H. Ellenson PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia. Clin. Cancer Res., October 15, 2006; 12(20): 5932 - 5935. [Abstract] [Full Text] [PDF]

				G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme Mol. Cancer Res., October 1, 2006; 4(10): 709 - 714. [Abstract] [Full Text] [PDF]

				N. Pore, Z. Jiang, H.-K. Shu, E. Bernhard, G. D. Kao, and A. Maity Akt1 Activation Can Augment Hypoxia-Inducible Factor-1{alpha} Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin-Independent Pathway Mol. Cancer Res., July 1, 2006; 4(7): 471 - 479. [Abstract] [Full Text] [PDF]

				P. R. Cutillas, A. Khwaja, M. Graupera, W. Pearce, S. Gharbi, M. Waterfield, and B. Vanhaesebroeck Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry PNAS, June 13, 2006; 103(24): 8959 - 8964. [Abstract] [Full Text] [PDF]

				G. Powis, N. Ihle, and D. L. Kirkpatrick Practicalities of drugging the phosphatidylinositol-3-kinase/akt cell survival signaling pathway. Clin. Cancer Res., May 15, 2006; 12(10): 2964 - 2966. [Full Text] [PDF]

				S.-i. Yaguchi, Y. Fukui, I. Koshimizu, H. Yoshimi, T. Matsuno, H. Gouda, S. Hirono, K. Yamazaki, and T. Yamori Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst, April 19, 2006; 98(8): 545 - 556. [Abstract] [Full Text] [PDF]

				W. Qiu, F. Schonleben, X. Li, D. J. Ho, L. G. Close, S. Manolidis, B. P. Bennett, and G. H. Su PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., March 1, 2006; 12(5): 1441 - 1446. [Abstract] [Full Text] [PDF]

				A. G. Bader, S. Kang, and P. K. Vogt Cancer-specific mutations in PIK3CA are oncogenic in vivo PNAS, January 31, 2006; 103(5): 1475 - 1479. [Abstract] [Full Text] [PDF]

				S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells Cancer Res., December 1, 2005; 65(23): 10992 - 11000. [Abstract] [Full Text] [PDF]

				G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro, and M. Santoro Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer Cancer Res., November 15, 2005; 65(22): 10199 - 10207. [Abstract] [Full Text] [PDF]

				I. Krop, M. T. Parker, N. Bloushtain-Qimron, D. Porter, R. Gelman, H. Sasaki, M. Maurer, M. B. Terry, R. Parsons, and K. Polyak HIN-1, an Inhibitor of Cell Growth, Invasion, and AKT Activation Cancer Res., November 1, 2005; 65(21): 9659 - 9669. [Abstract] [Full Text] [PDF]

				I. G. Campbell, S. E. Russell, W. A. Phillips, D. A. Levine, and J. Boyd PIK3CA Mutations in Ovarian Cancer Clin. Cancer Res., October 1, 2005; 11(19): 7042 - 7043. [Full Text] [PDF]

				J. Luo, C. L. Sobkiw, N. M. Logsdon, J. M. Watt, S. Signoretti, F. O'Connell, E. Shin, Y. Shim, L. Pao, B. G. Neel, et al. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase PNAS, July 19, 2005; 102(29): 10238 - 10243. [Abstract] [Full Text] [PDF]